13A-1100322
TW I828126、US 12,064,466 B2、EP pending
This invention reports that recombinant mouse PRAP1 protein (rPRAP1) directly binds to triglycerides (TG). Oral administration of rPRAP1 significantly reduces lipid absorption by promoting lipid excretion into feces, and lowers plasma TG levels. Patients with hypertriglyceridemia are predisposed to cardiovascular diseases and also show increased risk of acute pancreatitis. Due to the limitations of drug efficacy, intolerance, and various side-effects, none of current TG lowering medications alone provides a satisfactory effect. rPRAP1 can lower plasma TG levels by a mechanism distinct from that of current known TG-lowering drugs. Combined use of drugs with different therapeutic mechanisms can increase therapeutic efficacy and/or reduce undesired side effects. The present invention proposes to apply rPRAP1 and its derivatives in the treatment of hypertriglyceridemia or hypertriglyceridemia-related diseases.
- Recombinant PRAP1 lowers plasma triglyceride levels through a novel mechanism that is distinct from current available medications for patients with hypertriglyceridemia or related diseases.
- PRAP1-related therapy may be useful to treat patients with hypertriglyceridemia or related diseases that are non- or less responsive to currently available medications, e.g. niacin, fibrates, omega 3 fatty acids.
- Combined use of drugs with different therapeutic mechanisms (e.g. PRAP1-related therapy with niacin, fibrates, and/or omega 3 fatty acids) can increase therapeutic efficacy and/or reduce undesired side effects.
Recombinant PRAP1 protein and its derivatives can be used for the manufacture of a potential therapeutic agent in the treatment of hypertriglyceridemia or hypertriglyceridemia-related diseases.
Hsin-Fang Yang-Yen
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Recombinant PRAP1 protein and its derivatives as a novel drug to treat hypertriglyceridemia or hypertriglyceridemia-related diseases